COMPANY

Photocure

HQ: Oslo, Norway source · photocure.com ↗

Keywords: diagnostics Bladder Cancer Acne Vulgaris Cervical Intraepithelial Neoplasia Non-muscle Invasive Bladder Cancer Colon Cancer Intermediate or High-risk Bladder Cancer Cervical Dysplasia Colorectal Cancer Acne Hexvix hexaminolevulinate Methyl aminolevulinate (MAL) PDT

Location: Oslo, Norway · source · Oct 14, 2026

Profile checked Oct 10, 2026

23Trials (company is sponsor)

Timeline

Mar 25, 2026 Trial start —: Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy source ↗
Nov 3, 2022 Trial start Phase 3: Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer source ↗
Oct 1, 2015 Trial start Phase 3: A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting source ↗
2014-04 Trial start —: Blue Light Cystoscopy With Cysview® Registry source ↗
2011-12 Trial start Phase 2: Detection of Bladder Tumors After 30 Min Instillation of Hexvix source ↗
2011-05 Trial start Phase 2: A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris source ↗
2011-04 Trial start Phase 2: Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia source ↗
2010-08 Trial start Phase 2: Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients source ↗
2010-06 Trial start —: Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB source ↗
2009-11 Trial start Phase 1: An Open-label, Single-dose, Three Period Study to Determine the Pharmacokinetic Parameters of Hexaminolevulinate (HAL) Hydrochloride After Vaginal, Enema and Intravenous Administration of Hea source ↗
2009-08 Trial start Phase 2: Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT) source ↗
2009-02 Trial start Phase 1/Phase 2: An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the Colon source ↗
2009-01 Trial start Phase 2: Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1 source ↗
2008-05 Trial start Phase 2: Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris source ↗
2007-07 Trial start Phase 2: Safety and Efficacy Study of Topical Methyaminlevulinate (MAL) in Subjects With Facial Acne source ↗
2007-02 Trial start Phase 2: Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne source ↗
2006-08 Trial start Phase 1/Phase 2: A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions. source ↗
2006-07 Trial start Phase 1/Phase 2: Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study source ↗
2005-04 Trial start Phase 3: A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer source ↗
2005-03 Trial start Phase 1: Hexvix Photodynamic Therapy in Patients With Bladder Cancer source ↗
2005-01 Trial start Phase 3: Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy source ↗
2001-09 Trial start Phase 3: Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer source ↗

Upcoming milestones

2027-12 (ESTIMATED) · · Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy · NCT07144319
2028-12 (ESTIMATED) · · Blue Light Cystoscopy With Cysview® Registry · NCT02660645

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 23

Record	Title	Phase	Status	Start	Primary completion
NCT07144319	Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy	Not listed	Recruiting	Mar 25, 2026	2027-12 (estimated)
NCT02660645	Blue Light Cystoscopy With Cysview® Registry	Not listed	Recruiting	2014-04	2028-12 (estimated)
NCT05600322	Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer	Phase 3	Completed	Nov 3, 2022	Jul 12, 2023 (actual)
NCT01166230	Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB	Not listed	Completed	2010-06	2010-12 (actual)
NCT02560584	A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting	Phase 3	Completed	Oct 1, 2015	Apr 5, 2017 (actual)
NCT01256424	Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia	Phase 2	Completed	2011-04	2012-09 (actual)
NCT01160848	Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients	Phase 2	Completed	2010-08	2011-01 (actual)
NCT01347879	A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris	Phase 2	Completed	2011-05	2012-04 (actual)
NCT00933543	Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)	Phase 2	Completed	2009-08	2010-03 (actual)
NCT00052637	Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer	Phase 3	Completed	2001-09	2002-05 (actual)
NCT01344902	An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the Colon	Phase 1/Phase 2	Terminated	2009-02	2009-10 (actual)
NCT00412971	A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer	Phase 3	Completed	2005-04	2008-10 (actual)
NCT00233402	Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy	Phase 3	Completed	2005-01	2008-07 (actual)
NCT00594425	Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne	Phase 2	Completed	2007-02	2008-07 (actual)
NCT00673933	Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris	Phase 2	Completed	2008-05	2008-12 (actual)
NCT00708942	Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1	Phase 2	Terminated	2009-01	2012-01 (actual)
NCT01551407	Detection of Bladder Tumors After 30 Min Instillation of Hexvix	Phase 2	Terminated	2011-12	2012-06 (actual)
NCT01303991	Hexvix Photodynamic Therapy in Patients With Bladder Cancer	Phase 1	Completed	2005-03	2008-08 (actual)
NCT00369018	A Dose-finding Study of MAL and HAL Photodynamic Therapy of Cervical Premalignant Lesions.	Phase 1/Phase 2	Completed	2006-08	2009-07 (actual)
NCT01050309	An Open-label, Single-dose, Three Period Study to Determine the Pharmacokinetic Parameters of Hexaminolevulinate (HAL) Hydrochloride After Vaginal, Enema and Intravenous Administration of Healthy Female Volunteers	Phase 1	Completed	2009-11	2009-12 (actual)
NCT00285701	Early Detection of Polyps and Colon Cancer by Fluorescence Imaging - a Dose-finding Study	Phase 1/Phase 2	Completed	2006-07	2007-11 (actual)
NCT00833183	Safety and Efficacy Study of Topical Methyaminlevulinate (MAL) in Subjects With Facial Acne	Phase 2	Completed	2007-07	2008-07 (actual)
NCT00496171	Phase I Study of HAL Formulations Applied to the Cervix in Healthy Volunteers	I	Terminated	Not listed	Not listed